Global Macular Degeneration (AMD) and Other Retinal Diseases Market Insights and Forecast to 2028

Table Of Contents

1 Report Business Overview

1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Macular Degeneration 1.2.3 Diabetic Macular Edema 1.2.4 Diabetic Retinopathy(DR) 1.2.5 Retinal Vein Occlusion 1.2.6 Wet Age-Related Macular Degeneration (wAMD) 1.2.7 Dry Age-Related Macular Degeneration (dAMD) 1.2.8 Other 1.3 Market by Application 1.3.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Other 1.4 Study Objectives 1.5 Years Considered2 Global Growth Trends 2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Perspective (2017-2028) 2.2 Macular Degeneration (AMD) and Other Retinal Diseases Growth Trends by Region 2.2.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Region (2017-2022) 2.2.3 Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Region (2023-2028) 2.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Dynamics 2.3.1 Macular Degeneration (AMD) and Other Retinal Diseases Industry Trends 2.3.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers 2.3.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Challenges 2.3.4 Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints3 Competition Landscape by Key Players 3.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue 3.1.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue (2017-2022) 3.1.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Players (2017-2022) 3.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Macular Degeneration (AMD) and Other Retinal Diseases Revenue 3.4 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio 3.4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2021 3.5 Macular Degeneration (AMD) and Other Retinal Diseases Key Players Head office and Area Served 3.6 Key Players Macular Degeneration (AMD) and Other Retinal Diseases Product Solution and Service 3.7 Date of Enter into Macular Degeneration (AMD) and Other Retinal Diseases Market 3.8 Mergers & Acquisitions, Expansion Plans4 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Type 4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Type (2017-2022) 4.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2023-2028)5 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application 5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Application (2017-2022) 5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2023-2028)6 North America 6.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 6.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 6.2.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2017-2022) 6.2.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2023-2028) 6.2.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2017-2028) 6.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 6.3.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2017-2022) 6.3.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2023-2028) 6.3.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2017-2028) 6.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country 6.4.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) 6.4.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) 6.4.3 U.S. 6.4.4 Canada7 Europe 7.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 7.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 7.2.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2017-2022) 7.2.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2023-2028) 7.2.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2017-2028) 7.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 7.3.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2017-2022) 7.3.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2023-2028) 7.3.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2017-2028) 7.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country 7.4.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) 7.4.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries8 Asia-Pacific 8.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 8.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 8.2.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2017-2028) 8.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 8.3.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2017-2028) 8.4 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region 8.4.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 9.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 9.2.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2017-2022) 9.2.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2023-2028) 9.2.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2017-2028) 9.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 9.3.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2017-2022) 9.3.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2023-2028) 9.3.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2017-2028) 9.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country 9.4.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) 9.4.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil10 Middle East & Africa 10.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2017-2028) 10.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type 10.2.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type (2017-2028) 10.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application 10.3.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application (2017-2028) 10.4 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country 10.4.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE11 Key Players Profiles 11.1 Regeneron Pharmaceuticals 11.1.1 Regeneron Pharmaceuticals Company Details 11.1.2 Regeneron Pharmaceuticals Business Overview 11.1.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.1.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.1.5 Regeneron Pharmaceuticals Recent Developments 11.2 Bayer HealthCare 11.2.1 Bayer HealthCare Company Details 11.2.2 Bayer HealthCare Business Overview 11.2.3 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.2.4 Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.2.5 Bayer HealthCare Recent Developments 11.3 Novartis 11.3.1 Novartis Company Details 11.3.2 Novartis Business Overview 11.3.3 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.3.4 Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.3.5 Novartis Recent Developments 11.4 Roche 11.4.1 Roche Company Details 11.4.2 Roche Business Overview 11.4.3 Roche Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.4.4 Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.4.5 Roche Recent Developments 11.5 Kanghong Pharma 11.5.1 Kanghong Pharma Company Details 11.5.2 Kanghong Pharma Business Overview 11.5.3 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.5.4 Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.5.5 Kanghong Pharma Recent Developments 11.6 Merck 11.6.1 Merck Company Details 11.6.2 Merck Business Overview 11.6.3 Merck Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.6.4 Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.6.5 Merck Recent Developments 11.7 Allergan 11.7.1 Allergan Company Details 11.7.2 Allergan Business Overview 11.7.3 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.7.4 Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.7.5 Allergan Recent Developments 11.8 Santen Pharmaceutical 11.8.1 Santen Pharmaceutical Company Details 11.8.2 Santen Pharmaceutical Business Overview 11.8.3 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.8.4 Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.8.5 Santen Pharmaceutical Recent Developments 11.9 GlaxoSmithKline Pharmaceuticals 11.9.1 GlaxoSmithKline Pharmaceuticals Company Details 11.9.2 GlaxoSmithKline Pharmaceuticals Business Overview 11.9.3 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.9.4 GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.9.5 GlaxoSmithKline Pharmaceuticals Recent Developments 11.10 Pfizer 11.10.1 Pfizer Company Details 11.10.2 Pfizer Business Overview 11.10.3 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.10.4 Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.10.5 Pfizer Recent Developments 11.11 Acucela 11.11.1 Acucela Company Details 11.11.2 Acucela Business Overview 11.11.3 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.11.4 Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.11.5 Acucela Recent Developments 11.12 Valent Pharmaceuticals 11.12.1 Valent Pharmaceuticals Company Details 11.12.2 Valent Pharmaceuticals Business Overview 11.12.3 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.12.4 Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.12.5 Valent Pharmaceuticals Recent Developments 11.13 IVERIC 11.13.1 IVERIC Company Details 11.13.2 IVERIC Business Overview 11.13.3 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Introduction 11.13.4 IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2017-2022) 11.13.5 IVERIC Recent Developments12 Analyst's Viewpoints/Conclusions13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer